Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $322.0 million.

  • Zenas BioPharma's Liabilities and Shareholders Equity fell 20.18% to $322.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year change of. This contributed to the annual value of $370.0 million for FY2024, which is 442.63% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Liabilities and Shareholders Equity is $322.0 million, which was up 9.87% from $293.1 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Liabilities and Shareholders Equity high stood at $403.4 million for Q3 2024, and its period low was $68.2 million during Q4 2023.
  • Over the past 3 years, Zenas BioPharma's median Liabilities and Shareholders Equity value was $327.9 million (recorded in 2025), while the average stood at $298.4 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 442.63% in 2024, then dropped by 20.18% in 2025.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Liabilities and Shareholders Equity stood at $68.2 million in 2023, then spiked by 442.63% to $370.0 million in 2024, then declined by 20.18% to $322.0 million in 2025.
  • Its last three reported values are $322.0 million in Q3 2025, $293.1 million for Q2 2025, and $333.8 million during Q1 2025.